$0.11
(Market cap
$2,428 Mln
Revenue (TTM)
$1,334 Mln
P/E Ratio
14.4
P/B Ratio
2.8
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$117 Mln
-
ROE
0.1 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
9.4
-
Debt to Equity
1.4
-
Book Value
$19.3
-
EPS
$2.1
-
Face value
--
-
Shares outstanding
46,471,350
10 Years Aggregate
CFO
$1,682.51 Mln
EBITDA
$1,850.93 Mln
Net Profit
$467.93 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Haemonetics (HAE)
| -28.7 | -3.6 | -1.1 | -17.4 | -13.9 | 2.0 | 8.1 |
|
BSE Sensex*
| -11.1 | -2.1 | -8.9 | -7.5 | 6.6 | 9.1 | 11.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Haemonetics (HAE)
| 2.7 | -8.6 | 8.7 | 48.3 | -55.3 | 3.4 | 14.8 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Haemonetics (HAE)
|
57.1 | 2,427.7 | 1,334.0 | 97.3 | 14.4 | 11.4 | 14.4 | 2.8 |
| 7.9 | 5,441.6 | 6,552.2 | -551.4 | -4.3 | -9.9 | -- | 1.0 | |
| 260.0 | 6,838.7 | 2,589.9 | 168.8 | 21.4 | 2.5 | 42.5 | 1.0 | |
| 44.2 | 6,586.8 | 3,458.5 | -10.3 | 1.9 | -0.5 | -- | 2.7 | |
| 23.9 | 3,938.0 | 2,808.1 | 67.7 | 6.8 | 2.2 | 59 | 1.3 | |
| 142.2 | 7,950.8 | 551.4 | -189.3 | -15.6 | -26.3 | -- | 11.7 | |
| 96.7 | 6,124.5 | 1,546.2 | 279.0 | 15.0 | 23.9 | 22.5 | 5.0 | |
| 178.4 | 9,347.9 | 1,558.5 | 76.3 | 19.1 | 9.5 | 44.1 | 11.8 | |
| 323.0 | 12,653.3 | 1,454.3 | 171.1 | 11.1 | 12.1 | 74.1 | 8.6 | |
| 103.4 | 6,538.2 | 763.3 | 51.4 | 11.6 | 2.5 | 127.4 | 3.3 |
Shareholding Pattern
View DetailsAbout Haemonetics (HAE)
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting... software solutions, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. It also provides treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE closure products comprising VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, clinical specialists, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts. Address: 125 Summer Street, Boston, MA, United States, 02110 Read more
-
CEO, President & Director
Mr. Christopher A. Simon
-
CEO, President & Director
Mr. Christopher A. Simon
-
Headquarters
Boston, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Haemonetics (HAE)
What is the current share price of Haemonetics Corporation (HAE) Today?
The share price of Haemonetics Corporation (HAE) is $57.12 (NYSE) as of 14-May-2026 16:00 EDT. Haemonetics Corporation (HAE) has given a return of -13.89% in the last 3 years.
What is the current PB & PE ratio of Haemonetics Corporation (HAE)?
The P/E ratio of Haemonetics Corporation (HAE) is 14.39 times as on 12-May-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2026
|
26.77
|
2.91
|
|
2025
|
18.75
|
3.83
|
|
2024
|
37.32
|
4.57
|
|
2023
|
36.73
|
5.18
|
|
2022
|
74.85
|
4.33
|
What is the 52 Week High and Low of Haemonetics Corporation (HAE)?
The 52-week high and low of Haemonetics Corporation (HAE) are Rs 87.32 and Rs 47.32 as of 15-May-2026.
What is the market cap of Haemonetics Corporation (HAE)?
Haemonetics Corporation (HAE) has a market capitalisation of $ 2,428 Mln as on 12-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Haemonetics Corporation (HAE)?
Before investing in Haemonetics Corporation (HAE), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.